--- title: "Hologic | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.048 B" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/274201394.md" datetime: "2026-01-29T21:05:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274201394.md) - [en](https://longbridge.com/en/news/274201394.md) - [zh-HK](https://longbridge.com/zh-HK/news/274201394.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274201394.md) | [English](https://longbridge.com/en/news/274201394.md) # Hologic | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.048 B Revenue: As of FY2026 Q1, the actual value is USD 1.048 B, missing the estimate of USD 1.073 B. EPS: As of FY2026 Q1, the actual value is USD 0.79, missing the estimate of USD 0.9. EBIT: As of FY2026 Q1, the actual value is USD 244.9 M. ### Overall Financial Performance Hologic, Inc. reported total revenue of $1,047.8 million for the fiscal first quarter ended December 27, 2025, marking a 2.5% increase, or 1.3% on a constant currency basis, compared to the prior year period. Total Organic Revenue, excluding COVID-19 and related revenue, divested businesses, and the acquired Gynesonics business, increased by 2.9%, or 1.6% in constant currency. U.S. Revenue grew by 2.0% to $773.5 million. International Revenue increased by 4.0% to $274.3 million, but decreased by -1.0% on a constant currency basis. ### Profitability GAAP Gross Margin was 56.0%, a decrease of -80 basis points, primarily due to $15.3 million in increased tariff expenses. Non-GAAP Gross Margin stood at 60.1%, a decrease of -150 basis points. GAAP Operating Expenses were $349.4 million, a -0.4% decrease from $350.7 million in the prior year. Non-GAAP Operating Expenses decreased by -0.7% to $326.6 million from $329.0 million in the prior year. GAAP Operating Margin increased by 10 basis points to 22.6%. Non-GAAP Operating Margin was 29.0%, a decrease of -40 basis points, mainly due to higher tariff expenses partially offset by lower operating expenses. GAAP Net Income was $179.1 million, representing a -10.9% decrease from $201.0 million in the prior year. Non-GAAP Net Income decreased by -1.3% to $235.5 million from $238.6 million in the prior year. Adjusted EBITDA increased by 1.3% to $330.4 million from $326.0 million in the prior year. GAAP Net Margin was 17.1%, a decrease of -260 basis points. Non-GAAP Net Margin was 22.5%, a decrease of -90 basis points. ### Segment Revenue - **Diagnostics Revenue**: This segment reported $464.4 million, a decrease of -1.3%, or -2.7% in constant currency. - Cytology and Perinatal revenue was $126.8 million, an increase of 1.1% (reported) and a decrease of -1.1% (constant currency). - Molecular Diagnostics revenue was $329.2 million, a decrease of -3.5% (reported) and -4.6% (constant currency). - Blood Screening revenue was $8.4 million, an increase of 104.9% (reported and constant currency). - Organic Diagnostics (excluding COVID-19) revenue was $428.0 million, an increase of 1.2% (reported) and a decrease of -0.3% (constant currency). - Organic Molecular (excluding COVID-19) revenue was $301.2 million, an increase of 1.2% (reported) and 0.0% (constant currency). - **Breast Health Revenue**: This segment generated $375.9 million, an increase of 1.8%, or 0.8% in constant currency. - Breast Imaging revenue was $280.0 million, a decrease of -0.6% (reported) and -1.6% (constant currency). - Interventional Breast Solutions revenue was $95.9 million, an increase of 9.6% (reported) and 8.4% (constant currency). - Organic Breast Health revenue was $375.8 million, an increase of 1.9% (reported) and 0.8% (constant currency). - **GYN Surgical Revenue**: This segment’s revenue was $180.8 million, an increase of 8.7%, or 7.5% in constant currency. - Organic Surgical (excluding Gynesonics) revenue was $171.7 million, an increase of 3.2% (reported) and 2.0% (constant currency). - **Skeletal Health Revenue**: This segment reported $26.7 million, an increase of 69.0%, or 65.9% in constant currency. ### Cash Flow and Balance Sheet Cash Flow from Operations was $229.9 million in the first quarter, an increase of 21.4% from $189.3 million in the prior year. Cash and Cash Equivalents stood at $2.17 billion at quarter-end, up from $1,959.5 million at September 27, 2025. Short-term Investments amounted to $197 million. Total Principal Debt as of December 27, 2025, was $2,519.0 million. ### Other Metrics The Adjusted Net Leverage Ratio (net debt over adjusted EBITDA) was 0.3 times. Adjusted Return on Invested Capital (ROIC) was 13.9%, a decrease of -20 basis points compared to the prior year period. COVID-19 Revenue totaled $28.0 million, consisting of $4.4 million in assay revenue and $23.6 million in other related revenue, representing a decrease of -35.8%, or -36.3% in constant currency. ### Outlook / Guidance Hologic, Inc. is not providing annual or quarterly financial guidance for fiscal 2026 due to its agreement to be acquired by Blackstone and TPG. Consequently, the company will not host a conference call to discuss its first quarter 2026 financial results. ### 相關股票 - [Hologic (HOLX.US)](https://longbridge.com/zh-HK/quote/HOLX.US.md) ## 相關資訊與研究 - [Retirement Systems of Alabama Decreases Stock Holdings in Hologic, Inc. $HOLX](https://longbridge.com/zh-HK/news/281340112.md) - [Energy Transfer stock is up big in 2026. Is there still time to get in?](https://longbridge.com/zh-HK/news/281629741.md) - [Individual investors could get a rare shot at buying into SpaceX from day one](https://longbridge.com/zh-HK/news/281225223.md) - [Aehr Test Systems to Announce Third Quarter Fiscal 2026 Financial Results on April 7, 2026 | AEHR Stock News](https://longbridge.com/zh-HK/news/281009812.md) - [US 10 Year Note Futures Hold Key Support as Macro Crosscurrents Build](https://longbridge.com/zh-HK/news/281024783.md)